Welcome to our dedicated page for Telix Pharmaceuticals ADR SEC filings (Ticker: TLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Telix Pharmaceuticals Limited (TLX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including Form 20-F and a series of Form 6-K reports. As a foreign private issuer listed on the Nasdaq Global Select Market, Telix uses Form 6-K to furnish key announcements originally released on the Australian Securities Exchange (ASX) to U.S. investors.
Through these filings, readers can review clinical, regulatory, and financial updates that Telix has formally submitted to the U.S. Securities and Exchange Commission. Examples referenced in recent 6-Ks include press releases on CMS granting Transitional Pass-Through status for Gozellix, revenue and operational updates, regulatory correspondence for TLX250-CDx, and clinical trial milestones such as progress in the ProstACT Global study. Each 6-K typically attaches the underlying ASX announcement as an exhibit, preserving the full text for detailed analysis.
For investors evaluating Telix’s radiopharmaceutical portfolio, SEC filings complement ASX disclosures by providing an official record of developments in products like Illuccix, Gozellix, TLX101-CDx, TLX250-CDx, and therapeutic candidates in oncology and rare diseases. Annual reports on Form 20-F, referenced in company legal notices, contain broader information on risk factors, business description, and financial statements.
On Stock Titan, these filings are paired with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly understand the significance of new 6-K submissions, annual reports, and other disclosures. Investors can use this page to monitor Telix’s ongoing reporting obligations, track how clinical and regulatory events are reflected in official filings, and review the company’s historical SEC record, including exhibits related to clinical trials, reimbursement decisions, and capital markets activity.
Telix Pharmaceuticals Limited submitted a Form 6-K as a foreign private issuer, forwarding materials from its Annual General Meeting held in May 2026. The filing makes available the Chairman and CEO addresses, an AGM presentation, and the results of the AGM as exhibits for U.S. investors.
Telix Pharmaceuticals Ltd filed an initial Form 3 identifying David N. Gill as a director of the company. The filing’s transaction summary shows no reported purchases, sales, exercises, gifts, or other share movements, and net buy/sell activity is neutral in this excerpt.
Telix Pharmaceuticals Ltd director William R. Jellison has filed an initial Form 3, which is a statement of beneficial ownership for company insiders. This filing lists him as a director but does not report any share transactions or holdings changes, serving mainly as a baseline disclosure.
Telix Pharmaceuticals Ltd filed an initial Form 3 for board member Maria Rivas. This filing establishes her status as a director and provides a baseline disclosure of her beneficial ownership as an insider. The data provided shows no reported purchases, sales, exercises, gifts, or other equity transactions.
Telix Pharmaceuticals Ltd MD & Group CEO Dr. Christian Behrenbruch, through Elk River Holdings Pty Ltd, made two open-market purchases of Ordinary Shares. On April 28 and 29, he indirectly bought a combined 67,935 shares at average prices around $14.48 and $14.87 per share, reported in Australian Dollars. After these transactions, his indirect holdings rose to 20,742,935 Ordinary Shares. The filing notes that the reported prices are volume-weighted averages for multiple trades within specified price ranges.
Telix Pharmaceuticals Limited filed a Form 6-K as a foreign private issuer. The filing forwards to U.S. investors an Australian Securities Exchange announcement titled “Telix Announces Settlement of US$600M Convertible Bonds,” attached as Exhibit 99.1. The report is signed by Group General Counsel Christian Krautkramer.
Telix Pharmaceuticals Limited, a foreign private issuer, submitted a Form 6-K relating to its shareholder meeting materials. On April 21, 2026 in Melbourne, the company lodged with the Australian Securities Exchange an announcement titled “Telix Notice of AGM, Proxy Form and Online Guide,” which is furnished to U.S. investors as Exhibit 99.1.
Telix Pharmaceuticals Limited has priced and upsized a US$600 million Offering of 1.50% convertible bonds due on or about 22 April 2031, issued by its U.S. subsidiary and guaranteed by Telix and a U.S. affiliate. The Convertible Bonds are convertible into Telix ordinary shares at an initial conversion price of US$13.85 (~A$19.55) per share, a 37.5% premium to a A$14.22 reference share price. Telix will concurrently repurchase approximately A$637 million of its existing A$650 million convertible bonds due 2029, with the balance intended to be redeemed, materially extending its debt maturity profile. Settlement of the new Offering and the Concurrent Repurchase is expected on 22 April 2026, subject to customary conditions, and is supported by a stock borrow facility over 15 million shares for 11 months.
Telix Pharmaceuticals is launching an offering of US$550 million convertible notes due 2031 through a wholly owned subsidiary, guaranteed by Telix entities, to refinance its existing 2029 convertible bonds and fund general corporate purposes. The notes carry an expected coupon of 1.50–1.75% and a 35–37.5% conversion premium, with a 5‑year maturity and an investor put after year three.
The company also highlights strong recent performance, with 2025 group revenue of US$804 million, up 56% year over year, including US$622 million from Precision Medicine and US$40 million EBITDA. Q1 2026 revenue reached US$230 million, up 11% sequentially, and 2026 revenue guidance is US$950–970 million. Telix outlines a late‑stage radiopharma pipeline, near‑term regulatory milestones and a new collaboration with Regeneron that includes US$40 million upfront and up to US$2.1 billion in potential milestones.